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Slc26a11 on the V-ATPase is only mildly 
aff ected by alteration in the membrane 
potential. Taken together, these observa-
tions suggest that the V-ATPase is acti-
vated by intra cellular chloride and put 
forward a critical role of Slc26a11 in mod-
ulating intra cellular Cl   −   . 
 In summary, Xu  et al. 1 have identifi ed a 
possible novel regulator of the V-ATPase 
in renal intercalated cells. Th is study raises 
a number of exciting possibilities for iden-
tifying new regulatory mechanisms of 
renal acidifi cation. Particularly interesting 
is the fact that Slc26a11 may function in 
Cl   −   conductance mode or Cl   −   / HCO 3   −  
exchange mode, under conditions that 
remain to be determined. Incidentally, 
these results also emphasize the complex 
arrangement of transport proteins in the 
various types of intercalated cells, alto-
gether indicating that the functions of 
these cells are not yet totally understood 
( Figure 1 ). 
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 Choice of dialysis modality 
 Rajnish  Mehrotra 1 , 2 
 Few medical decisions have as profound an impact on every aspect of a 
patient ’ s life as the selection of dialysis modality by a patient with end-
stage renal disease. It remains uncertain whether the outcome 
differences seen between hemodialysis and peritoneal dialysis patients, 
if any, in observational studies are attributable to the dialysis modality. 
Such studies, thus, are insufficient to deny patients a choice in selecting 
their dialysis modality. 
 Kidney International (2011)  80, 909 – 911;  doi: 10.1038/ki.2011.262 
 Over the past three decades, scores of sin-
gle-center, multicenter, and national-reg-
istry studies have compared the outcomes 
of end-stage renal disease patients treated 
with hemodialysis (HD) and peritoneal 
dialysis (PD). Even though the results 
have not always been consistent, a few 
common themes emerged from the stud-
ies using cohorts from the 1990s. 1 First, 
although the early risk for death was lower 
in PD patients, the long-term patient and 
technique survival was not as good as 
achieved with HD. Second, the relative 
outcomes varied by age, diabetic status, 
and comorbidity status of patients —
 younger, nondiabetic patients with no 
additional comorbidity treated with PD 
had a considerably lower risk for death 
than those treated with HD, but older 
diabetic PD patients had a higher risk 
for death than the corresponding HD 
patients. 1 These results, however, have 
limited applicability for our current clini-
cal practice, as improvements in outcomes 
of PD patients have outpaced those seen 
with HD. Th us, in contemporary cohorts 
in the United States there is no signifi cant 
diff erence in the 4-, 5-, and 10-year sur-
vival of patients treated with HD or PD. 2,3 
Th e overall equivalency in outcomes with 
the two therapies in more recent cohorts 
has also been reported from Australia, 
New Zealand, Taiwan, and Colombia, 
regions with higher rates of PD utilization 
than seen in the United States. 3 Th e dif-
ferential improvement in outcomes has 
been seen for every subgroup of patient 
such that the higher risk for death in 
the older diabetics has attenuated in 
comparison with earlier cohort periods. 2 
Despite the multitude of these compari-
sons, the central question meant to be 
answered by these studies remains: are any 
of the diff erences in outcomes seen in any 
cohort or any subgroup thereof attribut-
able to the dialysis modality or a result of 
unmeasured diff erences in the character-
istics of the patients who choose a given 
modality? And is it appropriate to use data 
from such observational studies when dis-
cussing the dialysis treatment options 
with an individual patient? 
 It is with this background that one 
should interpret the results of the analyses 
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by Sens and colleagues that appear in this 
issue of  Kidney International . 4 Using data 
from the French Renal Epidemiology and 
Information Network (REIN) registry, the 
authors compared the outcomes of 4401 
end-stage renal disease patients with con-
gestive heart failure who started dialysis 
electively between 2001 and 2008 treated 
with HD ( n  =  3468) or PD ( n  =  933). Out-
comes (death or transplant) were ascer-
tained through 31 December 2008. In the 
primary analysis, the adjusted hazards for 
all-cause mortality were 47 % higher for 
patients treated with PD compared with 
HD. 4 Th e excess mortality in PD patients 
was primarily driven by a higher risk for 
cardiovascular death. The results were 
robust when the authors reanalyzed the 
data using propensity scores — a statistical 
method that attempts to account for the 
nonrandom assignment of patients to the 
two therapies by using the information 
available from known differences in 
demographic and clinical characteristics. 
Furthermore, the higher risk for death was 
evident in subgroups based on age, dia-
betic status, symptom severity, and renal 
function at the time of fi rst dialysis. 4 Th e 
authors conclude that, until results of ran-
domized controlled clinical trials are 
available, these results should inform 
clinical decision making for end-stage 
renal disease patients with congestive 
heart failure. 4 
 It is conceivable that these diff erences in 
outcomes are attributable to the dialysis 
modality — perhaps a consequence not of 
the selected therapy in itself but of how it 
is practiced. Because the primary underly-
ing comorbidity in these patients was con-
gestive heart failure and the most common 
cause of death was cardiovascular, it is 
reasonable to focus on the relative merits 
of each dialysis modality  vis- à -vis fl uid 
removal ( Figure 1 ). With HD, even though 
fl uid removal is intermittent, it is predict-
able for each dialysis session. Although 
hemodynamic instability during HD 
treatment remains a limitation, particu-
larly in patients with left  ventricular dys-
function, it can be overcome by maneuvers 
such as lowering of the dialysate tempera-
ture, sodium modeling, use of midodrine, 
or more frequent HD. 5 Th e health-care 
provider skill set necessary to achieve euv-
olemia with PD, however, is considerably 
diff erent from that needed with HD. It 
requires ongoing engagement and recali-
bration of the prescription by the patient, 
physician, and nurse based on dietary 
intake, catheter function, and residual 
renal function. 6 Furthermore, unlike with 
HD, the ultrafiltration with any given 
tonicity of dextrose for any given exchange 
on any given day cannot be predicted. 
Nevertheless, carefully designed PD pre-
scriptions can allow most patients to 
achieve euvolemia as with HD. 7 If indeed 
the diff erences in outcomes reported in 
the study by Sens  et al. 4 are attributable to 
the dialysis modality, the conclusion 
should not be to deny patients the choice 
of therapy. Instead, the most important 
lesson that should be learned is that there 
is a larger gap in care to achieve euvolemia 
for patients treated with PD than with 
HD. Unfortunately, national registries 
such as the REIN do not have suffi  cient 
granularity regarding dialysis prescrip-
tions to allow us to understand how best 
to change clinical practice in order to 
improve patient outcomes. Relevant infor-
mation that is oft en lacking in national 
registries includes not only the prescrip-
tion strategies listed for HD, but also 
details of PD prescription such as relative 
use of automated PD (particularly for high 
transporters), use of PD solutions like ico-
dextrin and hypertonic dextrose solutions, 
and appropriate adjustment of PD pre-
scriptions with either decline in residual 
renal function or change in peritoneal 
membrane function. 
 Alternatively, the differences in out-
comes may be a result of the inability of 
the statistical models to account for 
unmeasured diff erences in patients who 
choose a given dialysis modality. In the 
REIN cohort, the patients who chose PD 
had some characteristics that could 
adversely infl uence outcome. Th us, the 
mean age of PD patients was 3.5 years 
greater than that of those starting HD, and 
the former were more likely to have New 
York Heart Association stage III or IV 
symptoms, or coronary artery disease. 
Furthermore, the mean estimated glomer-
ular fi ltration rate of patients starting PD 
was about 3  ml / min per 1.73  m 2 higher 
than that of patients starting HD — a con-
sistent predictor of higher all-cause mor-
tality. Even though statistical models such 
as the ones used by Sens and colleagues 4 
attempt to account for these diff erences by 
including them as covariates, the risk of 
 ‘ residual confounding ’ remains. Residual 
confounding could arise either from 
unmeasured diff erences in the severity of 
included covariates (for example, in 
whether coronary artery disease is one-
vessel, two-vessel, or three-vessel disease) 
or from lack of information about known 
or unknown factors that are equally or 
more important in determining outcomes 
of end-stage renal failure patients with 
congestive heart failure. 
 A diagnosis of end-stage renal disease 
and the initiation of dialysis have a pro-
found impact on patients ’ lifestyle, and 
their emotional health. 8 Selection of a 
Peritoneal dialysisHemodialysis
Cons
• Precise prediction of daily
ultrafiltration volume not possible
• Greater dependence on patient
to adjust prescription in
response to daily fluctuations
in fluid status
Pros
• Gentle and sustained fluid
removal
• Better preservation of
residual renal function
• Ability to use cardioprotective
medications with lower risk for
hyperkalemia
Cons
• Hemodynamic instability, particularly
in presence of ventricular dysfunction
• Myocardial stunning with aggressive
ultrafiltration
Pros
• Predictable ultrafiltration with each session
• Frequent evaluation of volume status by
health-care provider
• Variety of therapeutic interventions to
manage intradialytic hypotension
 Figure 1  |  Some advantages and disadvantages of the two dialysis modalities  vis- à -vis fluid 
removal and management of congestive heart failure. 
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dialysis modality that best serves the 
patient ’ s lifestyle, expectations, and emo-
tional health can ease this transition. Th e 
only way to defi nitively determine whether 
diff erences in medical outcomes are attrib-
utable to a given dialysis modality is to 
undertake a randomized controlled trial. 
Th e launching of such a trial is being con-
sidered in China. Even if such a clinical 
trial is successful, it is highly unlikely that 
it will be adequately powered to inform 
decision making in subgroups of patients 
such as those with diabetes or congestive 
heart failure. In the absence of randomized 
controlled clinical trials, do observational 
studies provide enough certitude that they 
should inform a medical decision that has 
profound eff ects on virtually every aspect 
of a patient ’ s life? Th e issue of residual con-
founding is real and potentially substantial 
in a disease state as complex as end-stage 
renal disease. Over the past decades, ran-
domized controlled trials have upended 
the conventional wisdom of trying to 
achieve higher urea clearances or higher 
hemoglobin targets. 9,10 Th e magnitude of 
uncertainty with observational studies is 
too high to deny any patient with end-
stage renal disease, including those with 
congestive heart failure, a choice in the 
selection of their dialysis modality. Instead, 
such studies should be used to identify 
gaps in clinical care that should be targeted 
for improvement. 
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 Detrimental effects of dual 
ACEI – ARB therapy: is the 
(pro)renin receptor the 
culprit ? 
 Fernando  Elijovich 1 and  Cheryl L.  Laffer 1 
 Chan  et al. report increased mortality with angiotensin-converting 
enzyme inhibitors and angiotensin type 1 receptor blockers in 
hemodialysis patients, supporting emerging evidence that such dual 
therapy may be detrimental. We speculate that effects of reactive renin 
and prorenin release on the (pro)renin receptor may explain this 
apparent paradox, either through membrane-bound generation of 
angiotensin II or via stimulation of signal transduction pathways. 
Potential benefits of direct renin inhibitors and yet-to-be-developed 
(pro)renin receptor blockers are discussed. 
 Kidney International (2011)  80, 911 – 914;  doi: 10.1038/ki.2011.264 
 Th e renin – angiotensin system (RAS) plays 
a role in the target organ damage of cardio-
renal disorders, above and beyond its blood 
pressure effects. This may be due to the 
experimentally proven proinfl ammatory, 
pro-oxidative, and growth-promoting 
actions of angiotensin II (Ang II). Hence, 
clinical trials have shown that addition of 
angiotensin-converting enzyme inhibitors 
(ACEIs) or angiotensin type 1 (AT 1 ) recep-
tor blockers (ARBs) to baseline therapy 
reduces cardiovascular morbidity and 
mortality in patients with heart failure, 
hypertension, and atherosclerotic heart dis-
ease and slows progression of renal dysfunc-
tion in those with diabetic or nondiabetic 
glomerulopathies. 
 Th e kinetics of angiotensin-converting 
enzyme (ACE) inhibition by ACEIs, the 
noncompetitive albeit surmountable block-
ade of AT 1 by ARBs, and the feedback 
release of renin in response to these agents 
predict that full blockade of the RAS cannot 
be achieved when used individually. Test-
ing the speculation that more profound 
blockade of the RAS by the combination of 
ACEIs with ARBs would confer additional 
morbidity benefi ts has given controversial 
results. Hospitalization rates were reduced 
in patients with heart failure in the CHARM 
Added and Val-HeFT trials, but harm 
signals were detected in post-myocardial 
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